Literature DB >> 1378718

Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications.

P R Colville-Nash1, D L Scott.   

Abstract

Rheumatoid arthritis can be considered as one of the family of 'angiogenesis dependent diseases'. Angiogenesis in rheumatoid arthritis is controlled by a variety of factors found in the synovial fluid and pannus tissue. Modulation of the angiogenic component of the disease may alter the pathogenesis of the condition, and subsequent cartilage and joint destruction, by reducing the area of the endothelium in the pannus and restricting pannus growth. Current therapeutic strategies exert, to varying extents, an inhibitory effect on the angiogenic process. In particular, the mode of action of the slow acting antirheumatic drugs may be due to their effect on the angiogenic response. The development of novel angiostatic treatments for chronic inflammatory joint disease may lead to a new therapeutic approach in controlling disease progression.

Entities:  

Mesh:

Year:  1992        PMID: 1378718      PMCID: PMC1004784          DOI: 10.1136/ard.51.7.919

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  99 in total

Review 1.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

Authors:  J Folkman
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

2.  Stimulation of neovascularization by human rheumatoid synovial tissue macrophages.

Authors:  A E Koch; P J Polverini; S J Leibovich
Journal:  Arthritis Rheum       Date:  1986-04

3.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.

Authors:  A B Roberts; M B Sporn; R K Assoian; J M Smith; N S Roche; L M Wakefield; U I Heine; L A Liotta; V Falanga; J H Kehrl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor.

Authors:  A B Schreiber; M E Winkler; R Derynck
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

5.  Characteristic ribonucleolytic activity of human angiogenin.

Authors:  R Shapiro; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1986-06-17       Impact factor: 3.162

6.  The effects of platelet-derived growth factor in cultured microvessel endothelial cells.

Authors:  R S Bar; M Boes; B A Booth; B L Dake; S Henley; M N Hart
Journal:  Endocrinology       Date:  1989-04       Impact factor: 4.736

Review 7.  Cachectin and tumour necrosis factor as two sides of the same biological coin.

Authors:  B Beutler; A Cerami
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

8.  Amino acid sequence of human tumor derived angiogenin.

Authors:  D J Strydom; J W Fett; R R Lobb; E M Alderman; J L Bethune; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

9.  A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.

Authors:  R Crum; S Szabo; J Folkman
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

10.  Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response.

Authors:  A Baird; N Ling
Journal:  Biochem Biophys Res Commun       Date:  1987-01-30       Impact factor: 3.575

View more
  47 in total

1.  Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha.

Authors:  G Montrucchio; E Lupia; A de Martino; E Battaglia; M Arese; A Tizzani; F Bussolino; G Camussi
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Angiogenic growth factors in rheumatoid arthritis.

Authors:  Malte Schroeder; Lennart Viezens; Ina Fuhrhop; Wolfgang Rüther; Christian Schaefer; Britta Schwarzloh; Petra Algenstaedt; Bernd Fink; Nils Hansen-Algenstaedt
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

Review 3.  Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.

Authors:  N Garcia de la Torre; H E Turner; J A H Wass
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.

Authors:  M Majima; I Hayashi; M Muramatsu; J Katada; S Yamashina; M Katori
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 5.  Cellular adhesion molecules. Newly identified mediators of angiogenesis.

Authors:  P J Polverini
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.

Authors:  Hideki Amano; Izumi Haysahi; Satoko Yoshida; Hirokuni Yoshimura; Masataka Majima
Journal:  Hum Cell       Date:  2002-03       Impact factor: 4.174

7.  The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation.

Authors:  P R Colville-Nash; M el-Ghazaly; D A Willoughby
Journal:  Agents Actions       Date:  1993-01

8.  Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants.

Authors:  Y Hori; D E Hu; K Yasui; R L Smither; G A Gresham; T P Fan
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

10.  Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.

Authors:  Stacy M Plum; Eun J Park; Steve J Strawn; Elizabeth G Moore; Carolyn F Sidor; William E Fogler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.